McKesson Corp. defeated a whistleblower’s False Claims Act suit alleging that the pharmaceutical company submitted claims for cancer drugs to Medicare that were tainted by kickbacks.
Adam Hart alleged that McKesson violated the FCA by providing two drug pricing tools to doctors in exchange for their commitment to purchase drugs from McKesson. A New York federal district court dismissed the suit for lack of scienter in May 2022, and Hart filed a second amended complaint in June.
This complaint’s “new” information failed to include sufficient allegations to show that McKesson acted with knowledge that its conduct was unlawful, as required ...
Read Full Story: https://news.google.com/rss/articles/CBMidWh0dHBzOi8vbmV3cy5ibG9vbWJlcmdsYXcu...
The Department of the Attorney General says the man claiming to be the state’s chief technology officer at national conferences and on online platforms is not affiliated with the state of Hawaii a...